Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 12:00 source : Investor.assemblybio.com save search
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
Published: 2023-07-17 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 4.63%
abi-5366 candidate international virus
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
Published: 2023-04-18 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: -1.77%
H: 9.45%
C: -1.8%
abi-4334 candidate update pipeline trial
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Published: 2022-11-04 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 1.87%
H: 0.0%
C: -6.75%
meeting liver potential
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
Published: 2022-10-24 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 0.65%
H: 5.81%
C: 3.23%
meeting liver
Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
Published: 2022-08-24 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 2.59%
H: 4.04%
C: 1.52%
research infection
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
Published: 2022-06-22 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 0.98%
H: 4.83%
C: 4.35%
liver international
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
Published: 2022-06-21 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
research program
Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 1.96%
H: 4.81%
C: 2.4%
liver international
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
Published: 2022-06-06 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 4.55%
H: 1.45%
C: -2.9%
treatment hepatitis virus trial infection infections phase 2b chronic hepatitis b
Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022
Published: 2022-03-21 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: -0.56%
H: 20.22%
C: 12.92%
program research bioscience
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
Published: 2021-08-18 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 1.97%
H: 5.23%
C: 1.1%
Assembly Bio Announces Key Promotions to Leadership Team
Published: 2021-08-03 (Crawled : 12:00) - investor.assemblybio.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.27%
H: 1.02%
C: 0.96%
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 1.44%
H: 5.68%
C: 3.98%
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021
Published: 2021-06-23 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 2.27%
H: 0.74%
C: -1.97%
liver bioscience
Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021
Published: 2021-06-09 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 0.49%
H: 5.83%
C: 5.34%
liver
Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors
Published: 2021-05-24 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $13.48 1.58% 1.56% 5.6K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.2%
bioscience
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.